NEJM: Ruxolitinib is effective in second-line treatment of chronic graft-versus-host disease

Chronic graft-versus-host disease (GVHD) is a serious complication after allogeneic stem cell transplantation.
30-70% of allogeneic stem cell transplant patients will develop chronic GVHD, which is the main cause of complications and non-recurrence-related deaths
.

The first-line treatment for chronic GVHD patients is glucocorticoid therapy, but about 50% of patients are glucocorticoid tolerance or glucocorticoid-dependent, and there is currently a lack of second-line GVHD treatments other than glucocorticoid therapy

In a previous retrospective cohort study of

Patients over 12 years of age with moderate to severe glucocorticoid tolerance or glucocorticoid-dependent chronic GVHD participated in the study and were randomized to receive Ruxolitinib treatment (10 mg, twice a day) or control (10 common treatment regimens)
.

The primary endpoint of the study was the treatment response at 24 weeks, and the key secondary endpoints included disease-free survival and changes in the Lee Symptom Scale score

329 patients participated in the study, including 165 in the ruxolitinib group and 164 in the control group .
At 24 weeks, the treatment response rate of the ruxolitinib group was higher than that of the control group (49.
7% vs 25.
6%, OR=2.
99 )
.

The disease-free survival period of the ruxolitinib group was significantly longer than that of the control group (more than 18.

At 24 weeks, the treatment response rate of the ruxolitinib group was higher than that of the control group (49.

Differences in treatment response rate and disease-free survival rate between groups

Research suggests that on -versus-host disease patients in severe tolerance glucocorticoid or a glucocorticoid-dependent chronic graft, Lu Suoli erlotinib superior in improving the rate of therapeutic response, disease free survival, and prolonged improvement in symptom scores Existing treatment methods
.

On -versus-host disease patients in severe tolerance glucocorticoid or a glucocorticoid-dependent chronic graft, Lu Suoli imatinib over the prior treatment in improving the rate of therapeutic response, disease free survival, and prolonged improvement in symptom scores Means
.

On -versus-host disease patients in severe tolerance glucocorticoid or a glucocorticoid-dependent chronic graft, Lu Suoli imatinib over the prior treatment in improving the rate of therapeutic response, disease free survival, and prolonged improvement in symptom scores Means

Original source:

Robert Zeiser et al.

Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
Leave a message here